A Two-Period, Randomised, Crossover Study Designed to Evaluate the In Vivo Performance of a Modified Release Formulation of Alicaforsen in Healthy Male Subjects in the Fed and Fasted State
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
Price : $35 *
At a glance
- Drugs Alicaforsen (Primary)
- Indications Crohn's disease; Pouchitis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Atlantic Pharmaceuticals
- 06 Nov 2018 Status changed from active, no longer recruiting to completed.
- 03 May 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2018 Status changed from planning to recruiting.